Correlative single photon emission computed tomography imaging of [123I]altropane binding in the rat model of Parkinson's

Nuclear Medicine and Biology

Volumn 38, Issue 5, 2011, Pages 741-749

  Gleave, Jacqueline A ^a   Farncombe, Troy H ^b   Saab, Chantal ^b   Doering, Laurie C ^a  

^a MCMASTER UNIVERSITY   (Canada)

^b Hamilton Health Sciences ^*  (Canada)

Author keywords

123I altropane; Dopamine; Parkinson's disease; Single photon emission computed tomography (SPECT)

Indexed keywords

AMPHETAMINE; DOPAMINE; IODINE ALTROPANE I 123; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MOLECULAR IMAGING; MOLECULAR PROBE; NEURAL STEM CELL TRANSPLANTATION; NEUROIMAGING; NONHUMAN; OUTCOME ASSESSMENT; PARKINSON DISEASE; RAT; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; SUBSTANTIA NIGRA; THERAPY EFFECT; TREATMENT RESPONSE;

ANIMALS; BEHAVIOR, ANIMAL; BIOLOGICAL MARKERS; COCAINE; DISEASE MODELS, ANIMAL; DOPAMINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; IODINE RADIOISOTOPES; NEOSTRIATUM; NEURAL STEM CELLS; OXIDOPAMINE; PARKINSON DISEASE; RATS; RATS, SPRAGUE-DAWLEY; STEM CELL TRANSPLANTATION; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 79959654635     PISSN: 09698051     EISSN: 18729614     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2010.12.006     Document Type: Article

References (28)

1. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003, 302:819-822.
2. Dauer W., Przedborski S. Parkinson's disease: mechanisms and models. Neuron 2003, 39:889-909.
3. Chapuis S., Ouchchane L., Metz O., Gerbaud L., Durif F. Impact of the motor complications of Parkinson's disease on the quality of life. Mov Disord 2005, 20:224-230.
4. Ungerstedt U. Postsynaptic supersensitivity after 6-hydroxy-dopamine induced degeneration of the nigro-striatal dopamine system. Acta Physiol Scand Suppl 1971, 367:69-93.
5. Bjorklund L.M., Sanchez-Pernaute R., Chung S., Andersson T., Chen I.Y., McNaught K.S., et al. Embryonic stem cells develop into functional dopaminergic neurons after transplantation in a Parkinson rat model. Proc Natl Acad Sci U S A 2002, 99:2344-2349.
6. Benamer T.S., Patterson J., Grosset D.G., Booij J., de Bruin K., van Royen E., et al. Accurate differentiation of parkinsonism and essential tremor using visual assessment of [123I]-FP-CIT SPECT imaging: the [123I]-FP-CIT study group. Mov Disord 2000, 15:503-510.
7. Ravina B., Eidelberg D., Ahlskog J.E., Albin R.L., Brooks D.J., Carbon M., et al. The role of radiotracer imaging in Parkinson disease. Neurology 2005, 64:208-215.
8. Mozley P.D., Schneider J.S., Acton P.D., Plossl K., Stern M.B., Siderowf A., et al. Binding of [99mTc]TRODAT-1 to dopamine transporters in patients with Parkinson's disease and in healthy volunteers. J Nucl Med 2000, 41:584-589.
9. Marek K., Innis R., van Dyck C., Fussell B., Early M., Eberly S., et al. [123I]beta-CIT SPECT imaging assessment of the rate of Parkinson's disease progression. Neurology 2001, 57:2089-2094.
10. Kim H.J., Im J.H., Yang S.O., Moon D.H., Ryu J.S., Bong J.K., et al. Imaging and quantitation of dopamine transporters with iodine-123-IPT in normal and Parkinson's disease subjects. J Nucl Med 1997, 38:1703-1711.
11. Booij J., Tissingh G., Winogrodzka A., Boer G.J., Stoof J.C., Wolters E.C., et al. Practical benefit of [123I]FP-CIT SPET in the demonstration of the dopaminergic deficit in Parkinson's disease. Eur J Nucl Med 1997, 24:68-71.
12. Fischman A.J., Bonab A.A., Babich J.W., Palmer E.P., Alpert N.M., Elmaleh D.R., et al. Rapid detection of Parkinson's disease by SPECT with altropane: a selective ligand for dopamine transporters. Synapse 1998, 29:128-141.
13. Abi-Dargham A., Gandelman M.S., DeErausquin G.A., Zea-Ponce Y., Zoghbi S.S., Baldwin R.M., et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. J Nucl Med 1996, 37:1129-1133.
14. Kao P.F., Tzen K.Y., Yen T.C., Lu C.S., Weng Y.H., Wey S.P., et al. The optimal imaging time for [99Tcm]TRODAT-1/SPET in normal subjects and patients with Parkinson's disease. Nucl Med Commun 2001, 22:151-154.
15. Madras B.K., Meltzer P.C., Liang A.Y., Elmaleh D.R., Babich J., Fischman A.J. Altropane, a SPECT or PET imaging probe for dopamine neurons: I. Dopamine transporter binding in primate brain. Synapse 1998, 29:93-104.
16. Schaffer P., Gleave J.A., Lemon J.A., Reid L.C., Pacey L.K., Farncombe T.H., et al. Isostructural fluorescent and radioactive probes for monitoring neural stem and progenitor cell transplants. Nucl Med Biol 2008, 35:159-169.
17. Woodlee M.T., Kane J.R., Chang J., Cormack L.K., Schallert T. Enhanced function in the good forelimb of hemi-Parkinson rats: compensatory adaptation for contralateral postural instability?. Exp Neurol 2008, 211:511-517.
18. Schallert T., Woodlee M.T. Orienting and placing. The behavior of the laboratory rat: A handbook with tests 2005, 129-140. Oxford University Press, New York, NY. I.Q. Whishaw, B. Kolb (Eds.).
19. Madras B.K., Gracz L.M., Meltzer P.C., Liang A.Y., Elmaleh D.R., Kaufman M.J., et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: II. Distribution to dopamine-rich regions of primate brain. Synapse 1998, 29:105-115.
20. Fernandez H.H., Friedman J.H., Fischman A.J., Noto R.B., Lannon M.C. Is altropane SPECT more sensitive to fluoroDOPA PET for detecting early Parkinson's disease?. Med Sci Monit 2001, 7:1339-1343.
21. Madras B.K., Gracz L.M., Fahey M.A., Elmaleh D., Meltzer P.C., Liang A.Y., et al. Altropane, a SPECT or PET imaging probe for dopamine neurons: III. Human dopamine transporter in postmortem normal and Parkinson's diseased brain. Synapse 1998, 29:116-127.
22. Acton P.D., Choi S.R., Plossl K., Kung H.F. Quantification of dopamine transporters in the mouse brain using ultra-high resolution single-photon emission tomography. Eur J Nucl Med Mol Imaging 2002, 29:691-698.
23. Scherfler C., Donnemiller E., Schocke M., Dierkes K., Decristoforo C., Oberladstatter M., et al. Evaluation of striatal dopamine transporter function in rats by in vivo beta-[123I]CIT pinhole SPECT. Neuroimage 2002, 17:128-141.
24. Andringa G., Drukarch B., Bol J.G., de Bruin K., Sorman K., Habraken J.B., et al. Pinhole SPECT imaging of dopamine transporters correlates with dopamine transporter immunohistochemical analysis in the MPTP mouse model of Parkinson's disease. Neuroimage 2005, 26:1150-1158.
25. Alvarez-Fischer D., Blessmann G., Trosowski C., Behe M., Schurrat T., Hartmann A., et al. Quantitative [(123)I]FP-CIT pinhole SPECT imaging predicts striatal dopamine levels, but not number of nigral neurons in different mouse models of Parkinson's disease. Neuroimage 2007, 38:5-12.
26. Asenbaum S., Brucke T., Pirker W., Podreka I., Angelberger P., Wenger S., et al. Imaging of dopamine transporters with iodine-123-beta-CIT and SPECT in Parkinson's disease. J Nucl Med 1997, 38:1-6.
27. Seibyl J.P., Marek K.L., Quinlan D., Sheff K., Zoghbi S., Zea-Ponce Y., et al. Decreased single-photon emission computed tomographic [123I]beta-CIT striatal uptake correlates with symptom severity in Parkinson's disease. Ann Neurol 1995, 38:589-598.
28. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007, 69:1480-1490. Parkinson Study Group.